Dennis Chen

Corporate Officer/Principal en PROMIS NEUROSCIENCES, INC. .

Health Technology

Perfil

Dennis Chen is currently the Head of Manufacturing at ProMIS Neurosciences, Inc. He previously worked as the Director of Process Development & Manufacturing at Geron Corp.
and as the Director of CMC Regulatory Affairs at Intarcia Therapeutics, Inc.

Cargos activos de Dennis Chen

Empresas	Cargo	Inicio
PROMIS NEUROSCIENCES, INC.	Corporate Officer/Principal	-

Todos los cargos activos de Dennis Chen

Antiguos cargos conocidos de Dennis Chen.

Empresas	Cargo	Fin
GERON CORPORATION	Corporate Officer/Principal	-
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Dennis Chen.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Dennis Chen.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
GERON CORPORATION	Health Technology
PROMIS NEUROSCIENCES, INC.	Health Technology

Empresas privadas	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology